Strategies aimed at disrupting the synthesis of TGF-β have been shown to significantly ameliorate liver fibrosis in experimental models (Hsu et al, 2019; Hung et al, 2022; Lu et al, 2018; Xi et al, 2021). This evidence concerns the gene TGFB1 and Hepatic fibrosis.